Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Rev. Ciênc. Méd. Biol. (Impr.) ; 21(3): 562-568, 20221229. tab
Article in Portuguese | LILACS | ID: biblio-1416293

ABSTRACT

Introdução: o consumo de álcool é um fator de risco bem conhecido para induzir doença crônica do fígado. O álcool também é um cofator na patogênese induzida pelo vírus da hepatite C (VHC). A infecção crônica pelo VHC pode exacerbar a lesão hepática alcoólica por mecanismos que incluem aumento do estresse oxidativo. Portanto o VHC, concomitantemente com o consumo excessivo de álcool, induz diversos mecanismos fisiopatogênicos que contribuem para a diminuição da depuração viral e para a lesão hepática. Objetivos: 1 ­ avaliar a frequência de esteato-hepatite alcoólica em biópsias de pacientes portadores do vírus da hepatite C; 2 ­ estudar os estágios da fibrose hepática nesses pacientes versus pacientes com e sem ingestão de álcool; 3 ­ analisar os escores bioquímicos e antropométricos desses pacientes. Metodologia: estudo de corte transversal, com pacientes acompanhados no núcleo de hepatologia do Hospital Prof. Edgard Santos da Universidade Federal da Bahia, portadores de hepatite C, com laudos de biópsias disponíveis para avaliar presença de esteato-hepatite alcoólica comprovada pelo registro de consumo de gramas de álcool. Foram considerados etilistas homens que consumiam mais de 30 g por dia e mulheres com consumo maior do que 20 g por dia. As variáveis utilizadas basearam-se em critérios histológicos, epidemiológicos e clínicos aplicados a esses pacientes. Resultados: a amostra total de pacientes portadores de hepatite C analisados foi de 335, sendo 100 indivíduos considerados com ingestão elevada de álcool, e 28,9% dos casos da amostra. A presença de esteatose hepática sem esteato-hepatite foi em 34 indivíduos (10,15%), e os casos de esteato-hepatite aparecem em um total de 30 indivíduos (8,96%). A carga viral elevada dos pacientes, tendo como referência >800.000, esteve em n=102, com 30,4% dos casos de VHC. Conclusão: observou-se, na população de estudo, 43 % os portadores de VHC com uso excessivo de alcool, 8,9 6% tinham esteato-hepatiits e 10,15 % esteatose. Além disso, verificou-se que mais da metade desses pacientes (56,6%) apresentaram grau de fibrose moderada e 53,3%, atividade necroinflamatória leve. A comorbidade mais comum observada foi hipertensão arterial sistêmica (HAS), em 40% dos pacientes.


Introduction: alcohol consumption is a well-known risk factor for inducing chronic liver disease, alcohol is also a cofactor in the pathogenesis induced by Hepatitis C Virus (HCV). Chronic HCV infection can exacerbate alcoholic liver damage by mechanisms including increased oxidative stress. Therefore, HCV, concomitantly with excessive alcohol consumption, induces several pathophysiological mechanisms, which contribute to the decrease in viral clearance and liver damage. Objectives: 1 ­ to assess the frequency of alcoholic steatohepatitis in biopsies of patients with the hepatitis C virus, 2 ­ to study the stages of liver fibrosis in these patients versus in patients with or without alcohol intake, 3 ­ analyze biochemical and anthropometric scores of these patients. Methodology: cross-sectional study, with patients monitored at the hepatology center of Hospital Prof. Edgard Santos from the Federal University of Bahia, carriers of hepatitis C with biopsy reports available to assess the presence of alcoholic steatohepatitis proven by recording the consumption of grams of alcohol, considered an alcoholic being a man, who consumed more than 30 g per day and being woman more than 20g a day. The variables used were based on histological, epidemiological and clinical criteria applied to these patients. Results: the total sample of patients with hepatitis C analyzed was (n=335), with n=100 individuals considered to have high alcohol intake, and 28.9% of the cases in the sample. The presence of hepatic steatosis without steatohepatitis was in 34 individuals (10.15%), and cases of steatohepatitis appear in a total of n=30 individuals (8.96%).The high viral load of patients, with >800,000 as reference, was n=102, with 30.4% of cases of HCV. Conclusion: it was observed, in the study population, 43% of HCV carriers with excessive alcohol use, 8.96% had steatohepatitis and 10.15% steatosis. Furthermore, it was found that more than half of these patients (56.6%) had a moderate degree of fibrosis and 53.3% had mild necroinflammatory activity. The most common comorbidity observed was systemic arterial hypertension (SAH), in 40% of patients.


Subject(s)
Humans , Male , Female , Fibrosis , Hepatitis C , Hepacivirus , Ethanol , Fatty Liver , Binge Drinking , Liver , Liver Cirrhosis , Epidemiology, Descriptive , Cross-Sectional Studies
2.
Rev. colomb. gastroenterol ; 37(4): 434-443, oct.-dic. 2022. tab, graf
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1423839

ABSTRACT

Resumen La infección crónica por el virus de la hepatitis C (VHC) afecta a 58 millones de personas y es una importante causa de morbimortalidad alrededor del mundo. La reinfección por VHC es un problema creciente en personas con factores de riesgo como consumo pesado de alcohol, sexo anal, sexo grupal y compartir agujas y jeringas; este tipo de infección se define como un nuevo contagio de VHC con un genotipo viral diferente al de la primera infección en un paciente luego de lograr una respuesta viral sostenida (RVS). La reinfección se presenta, en parte, debido a la ausencia de estrategias de promoción y prevención. Teniendo en cuenta estos antecedentes, se han propuesto estrategias más pragmáticas para controlar la infección por VHC y evitar la reinfección, tales como la microeliminación. En el presente artículo se presenta un caso de un paciente que presenta alteración en los marcadores de la bioquímica hepática, por lo que se solicita una prueba diagnóstica de infección por VHC y luego genotipificación viral, y se evidenció una infección por VHC genotipo 1, subgenotipo 1A. Se inició el manejo con antivirales de acción directa y se documentó una adecuada RVS12. Tres meses después el paciente regresó a consulta y en los exámenes de control se evidenció una carga viral elevada de VHC, por lo que se solicitó genotipificación y se demostró una nueva infección por VHC genotipo 4.


Abstract Chronic hepatitis C (HCV) infection affects 58 million people and is a significant cause of morbidity and mortality worldwide. HCV reinfection is a growing problem in people with risk factors such as heavy alcohol use, anal sex, group sex, and sharing needles and syringes. This type of infection is defined as a new HCV infection with a different viral genotype than the first infection in a patient after achieving a sustained viral response (SVR). Reinfection occurs, in part, due to the absence of promotion and prevention strategies. Taking this background into account, more pragmatic approaches have been proposed to control HCV infection and avoid reinfection, such as micro elimination. This article reports the case of a patient with alterations in biochemical liver markers, for which a diagnostic test for HCV infection and then viral genotyping was requested. Infection by HCV genotype 1, subgenotype 1A, was evidenced. Management with direct-acting antivirals was started, and an adequate SVR12 was documented. Three months later, the patient returned, and the control tests showed a high HCV viral load, for which genotyping was requested, showing a new HCV genotype 4 infection.

4.
Rev. Urug. med. Interna ; 7(1)mar. 2022.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1387574

ABSTRACT

Resumen: Introducción: La infección crónica por el virus de la hepatitis C (VHC) es responsable de 400.000 muertes al año, asociadas fundamentalmente al desarrollo de cirrosis y carcinoma hepatocelular. El advenimiento de los nuevos antivirales de acción directa ha marcado un punto de inflexión en el tratamiento del VHC, llevando a casi 100% la curación de los pacientes tratados. En tal sentido, la OMS se ha fijado como objetivos para el año 2030, reducir un 90% las nuevas infecciones por el VHC y un 65% la mortalidad asociada a este virus, para lo cual es necesario el desarrollo de estrategias activas de diagnóstico y vinculación a la atención y tratamiento. El objetivo del trabajo es realizar un diagnóstico de situación de los pacientes infectados por el VHC en el Hospital Central de las Fuerzas Armadas (HCFFAA), e implementar y evaluar una estrategia secuencial de revinculación a la atención. Metodología: Se construyó la cascada de tratamiento mediante una estimación de los pacientes portadores de infección crónica por VHC basada en la prevalencia local y la revisión de historias clínicas de los pacientes asistidos en el servicio de Hepatología y Trasplante Hepático del HCFFAA. Se implementó una estrategia para contactar a los pacientes con infección por VHC de forma secuencial, buscando re-establecer el vínculo de estos con el servicio de salud, asegurando el acceso a la estadificación de la enfermedad hepática y al tratamiento antiviral. Resultados: La prevalencia global estimada de personas con infección crónica por VHC fue de 1.008 personas. De 135 pacientes con serología positiva, 113 tenían ARN confirmatorio, 76 habían recibido tratamiento y 70 habían alcanzado respuesta virológica sostenida. La implementación de la estrategia logró un aumento en la prescripción del tratamiento del 67% a 76% de los pacientes con infección crónica por VHC confirmada. Conclusiones: La implementación de la estrategia de revinculación fue exitosa, con un aumento de la prescripción del tratamiento antiviral en los pacientes candidatos a tratamiento. La búsqueda activa de los pacientes infectados no diagnosticados mediante el cribado es el siguiente paso para alcanzar los objetivos de erradicación.


Abstract: Introduction: Chronic infection by the hepatitis C virus (HCV) is responsible for 400,000 deaths per year, mainly associated with the development of cirrhosis and hepatocellular carcinoma. The advent of new direct-acting antivirals has marked a turning point in the treatment of HCV, leading to almost 100% cure of treated patients. In this sense, the WHO has set as objectives for the year 2030, to reduce new HCV infections by 90% and the mortality associated with this virus by 65%, for which it is necessary to develop active strategies for diagnosis and linkage to care and treatment. The objective of the work is to carry out a diagnosis of the situation of the patients infected by HCV in the Central Hospital of the Armed Forces (HCFFAA), and to implement and evaluate a sequential strategy of re-attachment to care. Methodology: The treatment cascade was constructed by estimating the number of patients with chronic HCV infection based on local prevalence and review of the medical records of patients seen in the Hepatology and Liver Transplant service of the HCFFAA. A strategy was implemented to contact patients with HCV infection sequentially, seeking to re-establish their link with the health service, ensuring access to liver disease staging and antiviral treatment. Results: The estimated global prevalence of people with chronic HCV infection was 1,008 people. Of 135 patients with positive serology, 113 had confirmatory RNA, 76 had received treatment, and 70 had achieved sustained virologic response. The implementation of the strategy achieved an increase in the prescription of treatment from 67% to 76% of patients with confirmed chronic HCV infection. Conclusions: The implementation of the rebinding strategy was successful, with an increase in the prescription of antiviral treatment in patients who are candidates for treatment. Active search for undiagnosed infected patients through screening is the next step to achieve eradication goals.


Resumo: Introdução: A infecção crônica pelo vírus da hepatite C (HCV) é responsável por 400.000 óbitos por ano, principalmente associada ao desenvolvimento de cirrose e carcinoma hepatocelular. O advento de novos antivirais de ação direta marcou um ponto de virada no tratamento do HCV, levando à cura de quase 100% dos pacientes tratados. Nesse sentido, a OMS estabeleceu como objetivos para o ano de 2030, reduzir em 90% as novas infecções por HCV e a mortalidade associada a este vírus em 65%, para o que é necessário desenvolver estratégias ativas de diagnóstico e vinculação aos cuidados e tratamento. O objetivo do trabalho é realizar um diagnóstico da situação dos pacientes infectados pelo HCV no Hospital Central das Forças Armadas (HCFFAA), e implementar e avaliar uma estratégia sequencial de reinserção aos cuidados. Metodologia: A cascata de tratamento foi construída estimando o número de pacientes com infecção crônica pelo HCV com base na prevalência local e revisão dos prontuários dos pacientes atendidos no serviço de Hepatologia e Transplante de Fígado do HCFFAA. Foi implantada uma estratégia de contato sequencial dos pacientes com infecção pelo HCV, buscando restabelecer o vínculo com o serviço de saúde, garantindo o acesso ao estadiamento da doença hepática e ao tratamento antiviral. Resultados: A prevalência global estimada de pessoas com infecção crônica pelo HCV foi de 1.008 pessoas. Dos 135 pacientes com sorologia positiva, 113 tiveram RNA confirmatório, 76 receberam tratamento e 70 alcançaram resposta virológica sustentada. A implementação da estratégia conseguiu um aumento na prescrição de tratamento de 67% para 76% dos pacientes com infecção crônica pelo HCV confirmada. Conclusões: A implementação da estratégia de religação foi bem sucedida, com aumento da prescrição do tratamento antiviral em pacientes candidatos ao tratamento. A busca ativa de pacientes infectados não diagnosticados por meio de triagem é o próximo passo para atingir as metas de erradicação.

5.
Braz. j. biol ; 82: e243283, 2022. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1278505

ABSTRACT

Infectious agents cause serious diseases in humans worldwide and are responsible for the high rate of morbidity and mortality. The prevalence and epidemiology of infectious disease (HCV) in the hospital visited patients referred by the physicians through the initial findings and their associated risk factors were studied in Swat. The data of 174 infected patients were collected during the period of 2015 to 2017 from two clinical laboratories of Tehsil Matta Swat. Inform consent form was taken before blood collection. After taking informed consent blood samples were collected and ICT test was performed and then ICT positive cases were conform through PCR. A total of 174 ICT positive samples [106 male and 68 females] were included in this study. Age was considered from 10 to 72 years. Of the 174 ICT strip positive, 99 [63 males, 36 females] were confirmed through PCR. The prevalence rate was recorded 56.89%. I.V/I.M injection was recorded in 100% of the individuals. Visits to the barber shop was reported in (58%) of the individuals, married individuals were (81.0), surgical operation was reported in (44.8%), sharing toothbrush was observed in (29.9%), piercing was reported in (39.7%), family history was reported in (26.4%), dental treatment was observed in (21.8%), jaundice were (13.2%) and tattooing was (1.7%). Blood transfusion, surgical operations, Jaundice, family history and dental treatment were found significant risk factors for acquiring HCV infection. It was concluded that proper implementation of precautionary measures should be needed to control the spread of HCV in far near future.


Agentes infecciosos causam doenças graves em humanos em todo o mundo, e são responsáveis pelo alto índice de morbimortalidade. A prevalência e a epidemiologia das doenças infecciosas no hospital que atendeu pacientes encaminhados pelos médicos por meio dos achados iniciais e seus fatores de risco associados foram estudadas em Peshawar. Os dados de 174 pacientes infectados foram coletados durante o período de 2015 a 2017 oriundos de dois laboratórios clínicos de Tehsil Matta Swat. O formulário de consentimento informado foi obtido antes da coleta de sangue. Após a obtenção do consentimento informado, foram coletadas amostras de sangue e foi realizado o teste ICT e, em seguida, os casos ICT positivos foram confirmados por PCR. Um total de 174 amostras ICT positivas [106 homens e 68 mulheres] foi incluído neste estudo. A idade considerada foi de 10 a 72 anos. Das 174 tiras de ICT positivas, 99 casos [63 homens, 36 mulheres] foram confirmados por PCR. A taxa de prevalência foi de 56,89%. A injeção IV / IM foi registrada em 100% dos indivíduos. A visita à barbearia foi relatada em (58%) dos indivíduos, os números de casados foram (81,0%), e a operação cirúrgica foi relatada em (44,8%), o compartilhamento de escova de dente foi observado em (29,9%), o piercing foi relatado em (39,7%), antecedentes familiares foram relatados em (26,4%), tratamento odontológico em (21,8%), icterícia (13,2%) e tatuagem em (1,7%). Transfusão de sangue, operações cirúrgicas, icterícia, histórico familiar e tratamento odontológico foram fatores de risco significativos para adquirir infecção por Vírus da Hepatite C (VHC). Concluiu-se que a implementação adequada de medidas de precaução deve ser necessária para controlar a propagação do VHC em um futuro próximo.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Young Adult , Hepatitis C/epidemiology , Hepacivirus , Pakistan/epidemiology , Prevalence , Risk Factors
6.
Braz. j. biol ; 82: 1-8, 2022. tab, ilus
Article in English | LILACS, VETINDEX | ID: biblio-1468547

ABSTRACT

Infectious agents cause serious diseases in humans worldwide and are responsible for the high rate of morbidity and mortality. The prevalence and epidemiology of infectious disease (HCV) in the hospital visited patients referred by the physicians through the initial findings and their associated risk factors were studied in Swat. The data of 174 infected patients were collected during the period of 2015 to 2017 from two clinical laboratories of Tehsil Matta Swat. Inform consent form was taken before blood collection. After taking informed consent blood samples were collected and ICT test was performed and then ICT positive cases were conform through PCR. A total of 174 ICT positive samples [106 male and 68 females] were included in this study. Age was considered from 10 to 72 years. Of the 174 ICT strip positive, 99 [63 males, 36 females] were confirmed through PCR. The prevalence rate was recorded 56.89%. I.V/I.M injection was recorded in 100% of the individuals. Visits to the barber shop was reported in (58%) of the individuals, married individuals were (81.0), surgical operation was reported in (44.8%), sharing toothbrush was observed in (29.9%), piercing was reported in (39.7%), family history was reported in (26.4%), dental treatment was observed in (21.8%), jaundice were (13.2%) and tattooing was (1.7%). Blood transfusion, surgical operations, Jaundice, family history and dental treatment were found significant risk factors for acquiring HCV infection. It was concluded that proper implementation of precautionary measures should be needed to control the spread of HCV in far near future.


Agentes infecciosos causam doenças graves em humanos em todo o mundo, e são responsáveis pelo alto índice de morbimortalidade. A prevalência e a epidemiologia das doenças infecciosas no hospital que atendeu pacientes encaminhados pelos médicos por meio dos achados iniciais e seus fatores de risco associados foram estudadas em Peshawar. Os dados de 174 pacientes infectados foram coletados durante o período de 2015 a 2017 oriundos de dois laboratórios clínicos de Tehsil Matta Swat. O formulário de consentimento informado foi obtido antes da coleta de sangue. Após a obtenção do consentimento informado, foram coletadas amostras de sangue e foi realizado o teste ICT e, em seguida, os casos ICT positivos foram confirmados por PCR. Um total de 174 amostras ICT positivas [106 homens e 68 mulheres] foi incluído neste estudo. A idade considerada foi de 10 a 72 anos. Das 174 tiras de ICT positivas, 99 casos [63 homens, 36 mulheres] foram confirmados por PCR. A taxa de prevalência foi de 56,89%. A injeção IV / IM foi registrada em 100% dos indivíduos. A visita à barbearia foi relatada em (58%) dos indivíduos, os números de casados foram (81,0%), e a operação cirúrgica foi relatada em (44,8%), o compartilhamento de escova de dente foi observado em (29,9%), o piercing foi relatado em (39,7%), antecedentes familiares foram relatados em (26,4%), tratamento odontológico em (21,8%), icterícia (13,2%) e tatuagem em (1,7%). Transfusão de sangue, operações cirúrgicas, icterícia, histórico familiar e tratamento odontológico foram fatores de risco significativos para adquirir infecção por Vírus da Hepatite C (VHC). Concluiu-se que a implementação adequada de medidas de precaução deve ser necessária para controlar a propagação do VHC em um futuro próximo.


Subject(s)
Male , Female , Humans , Child , Hepatitis C/epidemiology , Hepatitis C/blood , Hepatitis C/transmission
7.
Braz. j. biol ; 822022.
Article in English | LILACS-Express | LILACS, VETINDEX | ID: biblio-1468734

ABSTRACT

ABSTRACT Infectious agents cause serious diseases in humans worldwide and are responsible for the high rate of morbidity and mortality. The prevalence and epidemiology of infectious disease (HCV) in the hospital visited patients referred by the physicians through the initial findings and their associated risk factors were studied in Swat. The data of 174 infected patients were collected during the period of 2015 to 2017 from two clinical laboratories of Tehsil Matta Swat. Inform consent form was taken before blood collection. After taking informed consent blood samples were collected and ICT test was performed and then ICT positive cases were conform through PCR. A total of 174 ICT positive samples [106 male and 68 females] were included in this study. Age was considered from 10 to 72 years. Of the 174 ICT strip positive, 99 [63 males, 36 females] were confirmed through PCR. The prevalence rate was recorded 56.89%. I.V/I.M injection was recorded in 100% of the individuals. Visits to the barber shop was reported in (58%) of the individuals, married individuals were (81.0), surgical operation was reported in (44.8%), sharing toothbrush was observed in (29.9%), piercing was reported in (39.7%), family history was reported in (26.4%), dental treatment was observed in (21.8%), jaundice were (13.2%) and tattooing was (1.7%). Blood transfusion, surgical operations, Jaundice, family history and dental treatment were found significant risk factors for acquiring HCV infection. It was concluded that proper implementation of precautionary measures should be needed to control the spread of HCV in far near future.


RESUMO Agentes infecciosos causam doenças graves em humanos em todo o mundo, e são responsáveis pelo alto índice de morbimortalidade. A prevalência e a epidemiologia das doenças infecciosas no hospital que atendeu pacientes encaminhados pelos médicos por meio dos achados iniciais e seus fatores de risco associados foram estudadas em Peshawar. Os dados de 174 pacientes infectados foram coletados durante o período de 2015 a 2017 oriundos de dois laboratórios clínicos de Tehsil Matta Swat. O formulário de consentimento informado foi obtido antes da coleta de sangue. Após a obtenção do consentimento informado, foram coletadas amostras de sangue e foi realizado o teste ICT e, em seguida, os casos ICT positivos foram confirmados por PCR. Um total de 174 amostras ICT positivas [106 homens e 68 mulheres] foi incluído neste estudo. A idade considerada foi de 10 a 72 anos. Das 174 tiras de ICT positivas, 99 casos [63 homens, 36 mulheres] foram confirmados por PCR. A taxa de prevalência foi de 56,89%. A injeção IV / IM foi registrada em 100% dos indivíduos. A visita à barbearia foi relatada em (58%) dos indivíduos, os números de casados foram (81,0%), e a operação cirúrgica foi relatada em (44,8%), o compartilhamento de escova de dente foi observado em (29,9%), o piercing foi relatado em (39,7%), antecedentes familiares foram relatados em (26,4%), tratamento odontológico em (21,8%), icterícia (13,2%) e tatuagem em (1,7%). Transfusão de sangue, operações cirúrgicas, icterícia, histórico familiar e tratamento odontológico foram fatores de risco significativos para adquirir infecção por Vírus da Hepatite C (VHC). Concluiu-se que a implementação adequada de medidas de precaução deve ser necessária para controlar a propagação do VHC em um futuro próximo.

8.
Acta biol. colomb ; 26(1): 72-80, ene.-abr. 2021. graf
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1152670

ABSTRACT

RESUMEN El Virus de la Hepatitis C (VHC) codifica la proteína Core. Que, además de ser la subunidad de la cápside, participa en diferentes mecanismos de patogénesis de la infección por VHC. Dado que el sistema de replicación in vitro del VHC presenta limitaciones, el uso de vectores virales podría ser una herramienta útil para estudiar las propiedades de la proteína Core. Con el fin de validar el vector con el Virus del Bosque de Semliki (SFV) para el estudio de Core en células HepG2, se evaluó la expresión de la proteína verde fluorescente (GFP) y la proteína Core utilizando este vector viral. Las expresiones de GFP y Core se detectaron en células HepG2 transducidas con rSFV de 24 a 96 horas postransducción. La expresión de la proteína Core fue inferior a la expresión de GFP en las células HepG2. Teniendo en cuenta que la proteína Core del VHC puede regular la actividad del gen p53, se evaluó el nivel transcripcional de este gen. Se observó una disminución en el nivel de mARN de p53 en las células luego de la transducción, comparado con las células control. Aunque las células transducidas con rSFV-Core presentaron el menor nivel de mARN de p53, la diferencia no fue significativa comparada con las células transducidas con rSFV-GFP. Los resultados confirman que rSFV permite la expresión transitoria de proteínas heterólogas en líneas celulares de hepatoma humano. Se necesitan estudios adicionales para determinar si la expresión disminuida de Core puede deberse a degradación de la proteína viral.


ABSTRACT The Hepatitis C Virus (HCV) encodes the structural protein Core, which in addition to being the capsid subunit, participates in different mechanisms of HCV infection pathogenesis. Since HCV in vitro replication system has limitations, the use of viral vectors could be a useful tool to study the Core protein properties. To validate the Semliki Forest Virus (SFV) strategy in transduced HepG2 cells to study the HCV Core protein, the expression of green fluorescent protein (GFP) and Core protein expressions were detected 24 to 96 hours post-transduction in HepG2 cells transduced with rSFV. Core protein expression was lower than GFP expression in HepG2 cells. Since HCV Core protein can regulate the activity of the p53 gene, the transcriptional level of this gene was evaluated. A decrease in the level of p53 mRNA was observed in the cells after transduction, compared to the control cells. Although the cells transduced with rSFV-Core had the lowest level of p53 mRNA, the difference was not significant compared to cells transduced with rSFV-GFP. The results confirm that rSFV allows the transient expression of heterologous proteins in human hepatoma cell lines. Additional studies are needed to determine whether the decreased expression of Core may be due to the degradation of the viral protein.

9.
Actual. SIDA. infectol ; 28(108): 30-37, 20201000. fig, tab
Article in Spanish | LILACS | ID: biblio-1349405

ABSTRACT

La disfunción inmune asociada a la infección por el virus de la inmunodeficiencia humana (VIH) es generada por una estimulación crónica del sistema inmune secundaria a la imposibilidad del organismo de erradicar el virus. La misma se encuentra exacerbada en el contexto de la coinfección por el virus de la hepatitis C (VHC). La inflamación sistémica producto de la coinfección por ambos virus genera un aumento de la morbilidad y mortalidad en los individuos afectados. Son varios los mediadores solubles de activación inmunológica, como IP-10, TNF-α, IL-6, IL-1ß (marcadores de inflamación sistémica); IL-17 (linfocitos T CD4+ Th17); IL-2, IFN-γ (linfocitos T CD4+ Th1); IL-8 (inducción de neutrofilia); CD23s, ICAMs, CD14s, CD163s (marcadores de activación de monocitos/macrófagos), niveles circulantes de lipopolisacárido (LPS) (translocación bacteriana); entre otros. Actualmente se necesitan más estudios para lograr definir cuáles serían los biomarcadores de progresión óptimos para el seguimiento de los individuos coinfectados por VIH/VHC. El objetivo de esta revisión es realizar una reseña sobre los mecanismos inmunopatológicos de la infección por VIH/VHC involucrados en la inflamación, daño hepático y su impacto en la morbimortalidad de los individuos coinfectados


The immune dysfunction associated with Human Immunodeficiency Virus (HIV) infection is generated by a chronic stimulation of the immune system, because of the inability to eradicate the virus from the host. This immune dysfunction is exacerbated in the context of coinfection with Hepatitis C Virus (HCV). Systemic inflammation caused by coinfection with both viruses generates an increase in morbidity and mortality in affected individuals. There are several soluble mediators of immunological activation, such as IP-10, TNF-α, IL-6, IL-1ß (systemic inflammation markers); IL-17 (CD4+ T cells Th17); IL-2, IFN-γ (CD4+ T cells Th1); IL-8 (neutrophilia); CD23s, ICAMs, CD14s, CD163s, lipopolysaccharide (LPS) (monocyte/macrophage activation markers and bacterial translocation); among others. Currently, more studies are needed to define optimal progression biomarkers for the follow-up of HIV/HCV coinfected individuals. In this review, we focus on the immunopathological mechanisms of HIV/HCV infection involved in inflammation, liver damage and its impact on the morbidity and mortality of affected individuals


Subject(s)
Humans , Biomarkers , HIV Infections/immunology , Hepacivirus/immunology , Coinfection/immunology , Hepatitis/immunology , Immunity , Immune System Diseases , Inflammation/immunology
10.
Acta biol. colomb ; 24(3): 493-502, Sep.-Dec. 2019. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1054643

ABSTRACT

ABSTRACT Hepatitis C Virus belongs to the Flaviviridae family. One proposed mechanism of HCV persistence in the ability to infect hematopoietic cells, including Dendritic cells (DCs). HCV infection of DCs could impair their functions that represent one of the mechanisms, thus hampering viral clearance by the host immune system. Among HCV-encoded proteins, the highly conserved Core protein has been suggested to be responsible for the immunomodulatory properties of this Hepacivirus. Recombinant viral vectors expressing the HCV Core protein and allowing its transduction and therefore the expression of the protein into DCs could be useful tools for the analysis of the properties of the Core protein. Vaccinia Virus and retrovirus have been used to transduce human DCs. Likewise, gene transfer into DCs using Semliki Forest Virus has been reported. This study aimed to express the HCV Core protein in human monocyte-derived DCs using an SFV vector, in which the subgenomic RNA encoding the structural proteins was replaced by the HCV Core sequence and then analyze the effects of its expression on DCs functions.


RESUMEN El virus de la Hepatitis C (VHC) pertenece a la familia Flaviviridae. Uno de los mecanismos propuestos de la persistencia del VHC es la capacidad de infectar células hematopoyéticas, incluidas las células dendríticas (DCs). La infección por VHC de DCs podría alterar sus funciones y corresponde a uno de los mecanismos que impiden el aclaramiento de la infección por VHC por el sistema inmunitario del hospedero. Entre las proteínas codificadas por el VHC, se ha sugerido que la proteína Core, altamente conservada, es responsable de las propiedades inmunomoduladoras de este Hepacivirus. Los vectores virales recombinantes que expresan la proteína Core y permiten su transducción a DCs podrían ser herramientas útiles para el análisis de las propiedades de esta proteína. El virus Vaccinia y el retrovirus se han utilizado para la transducción de DCs humanas. Del mismo modo, la transducción de DCs usando el virus del bosque de Semliki ha sido reportada. El objetivo de este estudio fue expresar la proteína Core de VHC en DCs derivadas de monocitos humanos utilizando un vector de SFV, en el que el ARN subgenómico que codifica las proteínas estructurales fue reemplazado por la secuencia Core del VHC y evaluar los efectos de su expresión en las funciones de DCs.

11.
Kasmera ; 47(2): 148-152, 02-12-2019. tab, ilus
Article in Spanish | LILACS | ID: biblio-1046353

ABSTRACT

El objetivo de la presente investigación es determinar la presencia de anticuerpos contra el virus de la hepatitis C en la población general de la zona sur de Manabí-Ecuador. Se demostró la ausencia de anticuerpos contra VHC en la población estudiada, se necesitan estudios adicionales que abarquen una población mayor


The objective of this research is to determine the presence of antibodies against hepatitis C virus in the general population of the southern area of Manabí-Ecuador. The absence of HCV antibodies was demonstrated in the studied population, additional studies covering a larger population are needed

12.
Cienc. Salud (St. Domingo) ; 3(3): 35-41, 20191125. tab
Article in Spanish | LILACS | ID: biblio-1379080

ABSTRACT

Introducción: las coinfecciones con hepatitis virales y el VIH representan un riesgo por su alta transmisibilidad y complicaciones. Es de vital importancia que se puedan identificar las barreras de acceso y manejo de las coinfecciones del VIH y la Hepatitis B y C. El propósito del estudio es describir la cascada de atención para la coinfección de las hepatitis virales en personas viviendo con VIH/SIDA. Métodos: se delimitaron los indicadores de manejo y seguimiento de los pacientes monitoreados actualmente en clínicas de primer nivel de atención en Santo Domingo y Santiago. Los datos recopilados fueron analizados a partir de los registros escritos de los pacientes en seguimiento, para evaluar los datos epidemiológicos y serológicos que se obtuvieron de los archivos clínicos. Resultados: se demostró que un 100 % de los pacientes fueron enrolados, 85.7 % se consideraron como retenidos en el manejo de la coinfección VIH/VHB y solamente 71.4 % recibieron TARV basado en Tenofovir. La cascada de atención para la coinfección VIH/VHC muestra un vínculo de 87.5 % de los pacientes, 75 % fueron retenidos y ninguno recibió tratamiento. Conclusión: la identificación de los factores de riesgo que influyen en las brechas de la cascada es fundamental para optimizar el manejo y monitoreo de los pacientes coinfectados, teniendo en cuenta que es preciso poder reconocer aquellos infectados para iniciar tratamiento de inmediato y así prever secuelas citopatológicas hepáticas


Introduction: Co-infections of viral hepatitis and HIV represent a risk due to their high transmissibility and complications. It is vitally important that barriers to access and management of HIV and Hepatitis B and C co-infections can be identified. The purpose of the study is to describe the cascade of attention for the preparation of viral hepatitis in people living with HIV/AIDS. Methods: The management and follow-up indicators of the patients currently monitored in first-level care clinics in Santo Domingo and Santiago were delimited. The data collected was analyzed from the written records of the patients in follow-up to evaluate the epidemiological and serological data that was obtained from the clinical files. Results: It was demonstrated that 100% of the patients were enrolled, 85.7% were considered as retained in care of HIV / HBV coinfection and only 71.4% received ARTbased on Tenofovir. The cascade of care for HIV / HCV coinfection shows a linkage to care of 87.5% of patients, 75% were retained and none received treatment. Conclusions: Identifying the risk factors that influence the gaps in the cascade of care is essential to optimize the management and monitoring of coinfected patients, with special interest in those that might receive immediate treatment to prevent liver cytopathological sequelae


Subject(s)
HIV Infections , Hepatitis, Viral, Human , Delivery of Health Care, Integrated
13.
Salud ment ; 42(4): 191-201, Jul.-Aug. 2019. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1058954

ABSTRACT

Abstract Introduction Efforts to identify new cases of HIV, HVC and other STIs, through the application of quick tests, focus on people who inject drugs, without taking into account the fact that the use of alcohol and other drugs of abuse inhibits decision making, increasing the transmission of STIs through risky sexual practices. Accordingly, it is necessary to have detection algorithms that consider people who use multiple drugs to improve the identification of new cases and their subsequent linkage with health services. Objective This paper describes the development process of the OPB-APR model for the detection, counseling and referral of people with HIV and other STIs at addiction treatment centers. Method The procedure is divided into three phases: 1. A literature review to identify the basic concepts of HIV and other STIs, substance use, risky sexual behaviors, quick tests, and specialized psychological counseling; 2. A feasibility study in which a health professional is trained to implement the OPB-APR model; 3. Drafting of the final version. Results The final version of the OPB-APR model was obtained, which describes standardized procedures for detection, counseling and referral to health services. Discussion and conclusions The OPB-APR model aims to strengthen the public health system by increasing the coverage of services for the detection of HIV, HCV and other STIs. The above through the implementation of standardized procedures among specialized and non-specialized health professionals of addiction care centers.


Resumen Introducción Los esfuerzos para la identificación de nuevos casos de VIH, VHC y otras ITS, mediante la aplicación de pruebas rápidas, se centra en personas que se inyectan drogas, sin considerar que el consumo de alcohol y otras drogas de abuso inhiben la toma de decisiones incrementando el riesgo de contagio de ITS durante prácticas sexuales de riesgo. Por este motivo, es necesario contar con algoritmos de detección que consideren a personas con múltiples consumos para incrementar la identificación de nuevos casos y su posterior vinculación a servicios de salud. Objetivo Describir el proceso de desarrollo del modelo OPB-APR para la detección, orientación y referencia de personas con VIH y otras ITS en centros de tratamiento de adicciones. Método El procedimiento se dividió en tres fases: 1. Revisión de literatura para identificar conceptos básicos sobre el VIH y otras ITS, consumo de sustancias, conductas sexuales de riesgo, pruebas rápidas, y orientación psicológica especializada; 2. Estudio de factibilidad en el que se entrenó a profesionales de la saludpara implementar el modelo OPB-APR; 3. Integración de la versión final. Resultados Se obtuvo la versión final del modelo OPB-APR el cual describe procedimientos estandarizados para la detección, orientación y referencia a servicios de salud. Discusión y conclusión El modelo OPB-APR pretende fortalecer al sistema público de salud al incrementar la cobertura de servicios para la detección del VIH, VHC y otras ITS. Lo anterior mediante la implementación de procedimientos estandarizados entre los profesionales de la salud especializados y no especializados de centros para la atención de adicciones.

14.
Med. interna Méx ; 35(3): 344-348, may.-jun. 2019. tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1154806

ABSTRACT

Resumen: OBJETIVO: Reportar una serie de casos de artropatía relacionada con hepatitis C. MATERIAL Y MÉTODO: Estudio retrospectivo en el que de enero de 2015 a diciembre de 2017 se incluyeron pacientes con infección crónica por VHC y artropatía referidos a la consulta de reumatología. Se examinaron de manera retrospectiva factores de riesgo, factor reumatoide (FR), anticuerpo contra péptido cíclico citrulinado (anti-PCC), anticuerpos contra VHC, genotipo viral y enzimas. También se determinó la subclase de artropatía, existencia de erosiones y tratamiento. Se excluyeron los pacientes infectados con VHB. RESULTADOS: Se incluyeron 31 pacientes. Los factores de riesgo de infección por VHC se identificaron solamente en 28 casos, que incluyen transfusión sanguínea antes de 1992 (n = 12) o abuso de drogas intravenosas (n = 16). En seis casos coexistieron artritis reumatoide y VHC; todos fueron seropositivos a factor reumatoide y anti-PCC y tres casos mostraron erosiones. Nueve casos tuvieron poliartritis simétrica u oligoartritis no erosiva que semejaba artritis reumatoide y 16 casos tuvieron artralgias simples. En total, el factor reumatoide fue positivo en 77% y las enzimas estuvieron altas en seis casos. La combinación de sulfasalazina, cloroquina y prednisona a dosis bajas y antiinflamatorios fue comúnmente indicada. CONCLUSIÓN: Los pacientes con infección por VHC pueden padecer artralgias-artritis. El tipo de artropatía debe diferenciarse por la hepatotoxicidad de los fármacos modificadores de enfermedad. El anti-PCC es útil para distinguir artropatía relacionada con hepatitis C de artritis reumatoide.


Abstract: OBJECTIVE: To report a case series of HCV-related arthropathy. MATERIAL AND METHOD: A retrospective study was done from January 2015 to December 2017 with patients with chronic HCV infection and arthropathy referred to our rheumatology clinic. All the patients were retrospectively reviewed. Risk factors for HCV infection including blood transfusion or intravenous drug abuse, rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP), anti-HCV (ELISA), viral genotype, and enzymes levels were examined. The clinical presentation of joint involvement, erosions, and type of treatment were also studied. Patients seropositive to HBV were excluded. RESULTS: There were included 31 patients. Risk factors were identified in only 28 cases, including blood transfusion (12) before 1992 and intravenous drug abuse (16). Rheumatoid arthritis coexisting with hepatitis C was found in 6 cases; all of these had anti-CCP, RF and erosions in 3. Nine patients gave a history of mild, symmetric poliar- thritis or oligoarthritis no-erosive resembling classic rheumatoid arthritis. Sixteen patients presented polyarthralgias. In total, RF was present in 77% out of 31 patients. Elevated enzymes were seen in 6 cases. Sulphasalazine, chloroquine, low dose prednisone and NSAIDs were commonly prescribed. CONCLUSION: The patients with HCV infection can present arthralgias/arthritis. The type of arthropathy must be differentiated due to the hepatotoxicity of disease modifying drugs. Anti-PCC antibody is useful for distinguishing HCV-related arthropathy from rheumatoid arthritis.

15.
Med. interna Méx ; 34(3): 435-442, may.-jun. 2018. graf
Article in Spanish | LILACS | ID: biblio-976087

ABSTRACT

Resumen La infección por el virus de la hepatitis C (VHC) se distribuye en todo el mundo, frecuentemente se convierte en hepatitis crónica, cirrosis y hepatocarcinoma. El genoma del VHC es una molécula de ARN monocatenario, de polaridad positiva, de aproximadamente 9.6 kb de longitud. Esta revisión resume el conocimiento actual y los avances recientes en la investigación de la biología molecular del VHC.


Abstract Infection with hepatitis C virus (HCV), which is distributed worldwide, often becomes in chronic hepatitis, cirrhosis and hepatocellular carcinoma. The HCV genome is a single-stranded RNA molecule of positive polarity approximately 9.6 kb in length. This review summarizes the current knowledge of recent advances in the investigation of the molecular biology of HCV.

16.
Rev. Fac. Med. (Guatemala) ; 1(25 Segunda Época): 29-35, Jun - Dic 2018.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1127680

ABSTRACT

Introducción: A nivel mundial la cirrosis representa una causa importante de morbi-mortalidad. En Guatemala no se cuenta con datos sobre las etiologías de la misma ni su frecuencia. Además, se ha demostrado que los pacientes infectados por virus hepatotropos, progresan más rápido hacia la muerte que los pacientes con enfermedad hepática crónica de otras etiologías. Estos pacientes son el principal interés del estudio, ya que la progresión podría desacelerarse con el tratamiento antiviral adecuado. Objetivos: Evaluar la prevalencia de infección crónica por hepatitis B y C en pacientes cirróticos, las principales causas de la misma, motivos de consulta en la EMA (Emergencia de Medicina de Adultos) y coinfección con VIH. Metodología: Se llevó a cabo un estudio prospectivo de 143 records médicos en la EMA (Emergencia de Adultos) de Gastroenterología del Hospital General San Juan de Dios, en los meses de octubre del 2017 a enero del 2018. Resultados: La ingesta excesiva de alcohol fue la principal causa de cirrosis, mientras que, los VHB y VHC son las principales causas de hepatopatía crónicas en países de primer mundo. Palabras clave: cirrosis, VHB, VHC, virus hepatotropos, progresión


Introduction: Worldwide, liver cirrhosis represents an important cause of morbimortality. There is no available data in Guatemala, regarding its etiologies or frequency and since patients infected with hepatotropic viruses, such as HBV or HCV and cirrhosis, progress faster to death than patients with chronic hepatic disease of different etiologies it is a most to know its prevalence . Objectives: To know the prevalence of HBV and HCV and other causes of chronic hepatic disease as HIV coinfection in patients consulting the ER. Methods: A prospective of study 143 patient files was conducted at the Adult ER and the Gastroenterology Outpatient Clinic at Hospital General San Juan de Dios, from October 2017 to January 2018. Results: Excessive alcohol intake was the main cause of cirrhosis amongst our patients, meanwhile HBV and HCV are the main etiologies of chronic liver disease in first world countries. Key words: cirrhosis, HBV. HCV, hepatotropic viruses, progression

18.
Invest. clín ; 58(2): 154-167, jun. 2017. ilus, tab
Article in Spanish | LILACS | ID: biblio-893531

ABSTRACT

Durante la infección por el virus de la hepatitis C (VHC), los anticuerpos específicos aparecen varias semanas posterior a la exposición, van dirigidos contra las diversas proteínas del virus incluyendo anticuerpos contra la envoltura viral (E2)y la proteína no estructural 2 (NS2). En este trabajo se diseñó un ensayo casero de ELISA que incorpora, además de NS3, NS5a, NS5b y el core, a las proteínas E2 y NS2 del VHC en sustitución de NS4, con el fin de evaluar su capacidad diagnóstica en comparación con un estuche comercial de 4ta generación. La validación de la prueba casera demostró una especificidad y sensibilidad similar a las obtenidas con el estuche comercial de 4ta generación (Biokit©), con un índice kappa igual a 0,969, al compararse con el mismo. Esto sugiere que la prueba diseñada podría utilizarse de manera segura para la detección de anticuerpos VHC específicos de tipo IgG para el diagnóstico de la hepatitis C y constituirse como una alternativa de producción nacional más económica.


During hepatitis C (HCV) infection specific antibodies appear several weeks after exposure, including viral envelope (E2) and non-structural protein 2 ( NS2). In this work we designed an in-house ELISA assay, that incorporate beside NS3, NS5a, NS5b and core, the HCVE2 and NS2 proteins in substitution of NS4, in order to evaluate its diagnostic utility as compared to a fourth generation commercial kit. The in-house test demonstrated a specificity and sensitivity similar to those obtained with the commercial kit, with a kappa index equal to 0.969, when it was compared with the 4th generation commercial kit (BioelisaBiokit ©), suggesting that our test could be used for the diagnosis of specific IgG antibodies detection against hepatitis C and to become a more economic national alternative.

20.
Rev. habanera cienc. méd ; 16(2): 199-216, mar.-abr. 2017.
Article in Spanish | LILACS, CUMED | ID: biblio-845275

ABSTRACT

Introducción: Las terapias contra el virus de la Hepatitis C han evolucionado vertiginosamente con el desarrollo de los antivirales de acción directa (AADs). Los nuevos regímenes han conseguido igualar las tasas de respuesta al tratamiento en los monoinfectados y los coinfectados con VIH, una población tradicionalmente difícil de tratar debido a la elevada morbimortalidad hepática y sistémica, reacciones adversas e interacciones medicamentosas. Objetivo: Analizar las opciones farmacoterapéuticas más modernas disponibles para los pacientes coinfectados con VIH y VHC, con énfasis en los nuevos antivirales de acción directa, a fin de ofrecer una herramienta útil en el abordaje terapéutico en estos pacientes. Material y métodos: Se revisaron artículos originales, ensayos clínicos y revisiones sistemáticas hasta septiembre de 2016, bases de datos internacionales de interacciones medicamentosas y Guías de Práctica Clínica actualizadas. Desarrollo: Las terapias contra el virus de la Hepatitis C (VHC) han evolucionado vertiginosamente con el desarrollo de los antivirales de acción directa (AADs). Los nuevos regímenes han conseguido igualar las tasas de respuesta al tratamiento en los monoinfectados y los coinfectados con VIH, una población tradicionalmente difícil de tratar que, además, asociaba una elevada morbimortalidad hepática y sistémica, más reacciones adversas y complejas interacciones medicamentosas. Conclusiones: En este nuevo escenario es fundamental dedicar esfuerzos a identificar el elevado porcentaje de infectados no diagnosticados, potenciales interacciones, especialmente con fármacos para patologías asociadas al envejecimiento de los pacientes, reacciones adversas a medio-largo plazos y desarrollo de resistencias, además de garantizar la cobertura universal en todos los contextos clínicos(AU)


Introduction:Therapies for hepatitis C virus (HCV) have rapidly evolved with the development of direct-acting antiviral agents. New regimens, achieve an equate response rates to treatment in cases of HCV mono-infected and HIV/HCV co-infected; a population traditionally difficult to treat due to a high hepatic and systemic morbidity-mortality, adverse reactions and drug interactions. Objective: To analyse the current Pharma-therapeutic options available for co-infected HIV-HCV patients, with emphasis I the new direct-acting antiviral agents, in order to offer a useful tool for the therapeutic approach in these patients. Material and Methods: Original articles, clinical studies and systematic reviews until September 2016 were carried out, as well as international drug interactions databases and updated Practical Guidelines. Development: Therapies for hepatitis C virus (HCV) have rapidly evolved with the development of direct-acting antiviral agents. New regimens achieve an equate response rates to treatment in HCV mono-infected and HIV/HCV co-infected; a population traditionally difficult to treat, which also associate a high hepatic and systemic morbidity-mortality, adverse reactions and complex drug interactions. Conclusions: In this new scenario efforts must be addressed to identify the high percentage of undiagnosed patients; potential interactions, especially with drugs related with patient aging; medium and long-term adverse reactions and development of drug resistances, as well as to guarantee universal coverage in all clinical contexts(AU)


Subject(s)
Humans , Male , Female , Comorbidity , HIV Infections/therapy , Hepatitis C, Chronic/therapy , Hepacivirus/pathogenicity , Coinfection/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL